ARTICLE | Company News
Zai gets China rights to Hanmi's EGFR inhibitor
November 24, 2015 4:00 AM UTC
Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940) granted Zai Laboratory Ltd. (Shanghai, China) exclusive rights in China to HM61713 to treat EGFR mutation-positive non-small cell lung cancer (NSCLC). The deal includes rights in Hong Kong and Macau. Financial terms weren't disclosed.
In July, Hanmi granted Boehringer Ingelheim GmbH (Ingelheim, Germany) exclusive, worldwide rights to the third-generation EGFR mutant-selective inhibitor outside South Korea, China and Hong Kong. Hanmi received $50 million up front in that deal, and is eligible for $680 million in milestones plus double-digit royalties. ...